FDA inspections, Form 483s and warning letters

In fiscal 2025, FDA investigators carried out 1,248 drug quality inspections, 702 of them in the United States and 546 in other countries. Counting 61 more done by partner regulators, the agency closed out 1,309 inspections that year and rated 18 percent of them Official Action Indicated, its finding that a plant's state of compliance was unacceptable. The figures come from the agency's FY2025 Report on the State of Pharmaceutical Quality¹.

The year before, FDA sent 105 drug quality warning letters to manufacturing sites, the most in five years, according to the FY2024 edition² of the same report. Foreign letters rose from 35 to 64 while domestic ones fell from 59 to 41.

Inspections are FDA's main check on whether a manufacturer follows current good manufacturing practice, the rules in 21 CFR Part 211 that GxRadar's CGMP explainer walks through. What happens after an inspection follows a predictable path, and most of the paperwork it generates (Form 483s, classifications, warning letters, import alerts) ends up public. Reading those documents correctly matters, because a 483 is often reported as if it were a verdict, and it is not one.

How FDA picks the plants

FDA runs several kinds of drug inspections, described on its pharmaceutical inspections page⁴. Surveillance inspections check ongoing compliance at plants already making products. For-cause inspections follow a specific signal, such as complaints or a recall. Pre-approval inspections look at a facility named in a pending application, and follow-up inspections verify that earlier problems were fixed.

Surveillance visits are assigned by a risk model. The factors FDA lists in its risk-based approach⁶ include the type of facility, its compliance history (including whether it has been inspected in the past four years), hazard signals such as recalls, the inherent risk of its products (sterile injectables rank above over-the-counter tablets) and whether a trusted foreign regulator has inspected it recently.

That model replaced a lopsided rule. "Before 2012, the law required us to inspect domestic facilities at a two-year interval, but was silent on frequency for foreign establishments, regardless of their relative risk," FDA told Congress in 2016 testimony⁷. Section 705 of the Food and Drug Administration Safety and Innovation Act of 2012⁸, the same law that created generic drug user fees (see how GDUFA works), replaced it with risk-based inspection frequency that applies to plants in any country.

Visits, records requests and partner inspections

The FY2025 total of 1,309 included 61 inspections by partner regulators under mutual recognition agreements with the European Union (in force since 2017), the United Kingdom (2021) and Switzerland (2023). In fiscal 2024, FDA had conducted 972 inspections, 56 percent of them abroad; our piece on FDA drug inspections by the numbers follows the trend year by year.

FDA can also ask for documents instead of visiting. Section 704(a)(4) of the Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 374⁹, lets it request records "in advance of or in lieu of an inspection." In fiscal 2025 it used 141 such records reviews to support application decisions, 74 percent of them sent to foreign sites, most often in India and China. Foreign plants supply much of the US generic market; GxRadar's piece on where drug ingredients come from has the geography.

The Form 483 and its limits

At the end of an inspection, if investigators saw conditions that in their judgment may violate the law, they hand plant management a Form FDA 483, formally titled Inspectional Observations. Each observation is read and discussed with senior management before the investigators leave. For generic drug facilities in fiscal 2025, the median time from the start of an inspection to the 483 was five calendar days, according to the GDUFA performance report³.

FDA's Form 483 FAQ⁵ sets out the limits. A 483 is not a final agency determination that the company broke the law. It is not a complete list of every possible problem, only what investigators observed and judged significant. Companies are encouraged to respond in writing with a corrective action plan and generally have 15 business days for that voluntary reply. FDA then weighs the 483, the investigator's establishment inspection report, any evidence collected and the company's response.

NAI, VAI and OAI

FDA classifies each inspection, aiming to finish within 90 days. No Action Indicated (NAI) means an acceptable state of compliance, usually with no 483 issued. Voluntary Action Indicated (VAI) means objectionable conditions were found but the company can correct them on its own. Official Action Indicated (OAI) means an unacceptable state of compliance and a recommendation for regulatory action. The FY2025 quality report¹ breaks the results out by region.

FDA flagged the US OAI rate as significantly above the global average and China's as significantly below it. Raw rates reflect which sites FDA chose to inspect, so they are not a ranking of countries. An OAI rating has consequences: FDA may withhold approval of pending applications that list the facility and refuse export certificates, and it generally lifts OAI status only after verifying corrections at a follow-up inspection.

Warning letters, import alerts and court action

Warning letters are the most visible step, and FDA posts them in a searchable database on its website. A company that fixes the cited problems can receive a close-out letter, but only after FDA verifies the corrections, usually through another inspection. When the problem has already reached shipped product, a recall may run in parallel; GxRadar's count of recall reasons shows CGMP deviations behind 654 recall events since 2012, and the recall tracker lists recent ones.

Import alerts are FDA's main lever over foreign plants. Under section 801 of the Act, 21 U.S.C. 381¹⁰, FDA can refuse admission to products that appear to violate the law, and firms or products on an alert's red list face detention without physical examination. FDA's import alerts page¹¹ explains the lists, and GxRadar's explainer on how import alerts work goes further. The main GMP-based alert for drugs is Import Alert 66-40. In fiscal 2024 FDA added 75 sites to quality-related import alerts, including 66-40, according to the FY2024 report². China accounted for 39 percent of them, and more than 60 percent of the additions came from records requests rather than on-site inspections.

Blocking a plant's output can tighten supply when few others make the same drug. That link between quality enforcement and shortages is covered in why drug shortages happen.

How long problems last

Resolution is slow. For generic drug facilities, the GDUFA FY2025 report³ gives a median of 169 days from a 483 to a warning letter, 144 days from a 483 to an import alert and 945 days from a warning letter to resolution of OAI status. Some firms never adequately remediate, and their compliance actions stay open indefinitely.

FDA generally posts final inspection classifications and warning letters to its public data dashboard, which covers inspections back to 2009, according to the agency's inspections and compliance page⁴.